[go: up one dir, main page]

MX374724B - Derivados de carbazol. - Google Patents

Derivados de carbazol.

Info

Publication number
MX374724B
MX374724B MX2017005255A MX2017005255A MX374724B MX 374724 B MX374724 B MX 374724B MX 2017005255 A MX2017005255 A MX 2017005255A MX 2017005255 A MX2017005255 A MX 2017005255A MX 374724 B MX374724 B MX 374724B
Authority
MX
Mexico
Prior art keywords
compounds
disclosed
carbazole derivatives
formula
diseases
Prior art date
Application number
MX2017005255A
Other languages
English (en)
Other versions
MX2017005255A (es
Inventor
Douglas G Batt
John E Macor
Joseph A Tino
Qingjie Liu
Saleem Ahmad
Satheesh Kesavan Nair
Scott Hunter Watterson
Tarun Kumar Maishal
Original Assignee
Bristol Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX374724(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Company filed Critical Bristol Myers Squibb Company
Publication of MX2017005255A publication Critical patent/MX2017005255A/es
Publication of MX374724B publication Critical patent/MX374724B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se describen los compuestos de la fórmula (I): (ver Fórmula) o una de sus sales, en donde: Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, y R7d se definen en la presente. También se describen métodos de uso de tales compuestos como inhibidores de la tirosina cinasa de Bruton (Btk) y composiciones farmacéuticas que comprenden tales compuestos. Estos compuestos son de utilidad en el tratamiento, prevención o lentificación de la progresión de enfermedades o trastornos en una variedad de áreas terapéuticas, tales como enfermedades autoinmunes y enfermedad vascular.
MX2017005255A 2014-10-24 2015-10-23 Derivados de carbazol. MX374724B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (2)

Publication Number Publication Date
MX2017005255A MX2017005255A (es) 2017-08-18
MX374724B true MX374724B (es) 2025-03-06

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005255A MX374724B (es) 2014-10-24 2015-10-23 Derivados de carbazol.

Country Status (34)

Country Link
US (3) US10266491B2 (es)
EP (1) EP3209651B9 (es)
JP (1) JP6599983B2 (es)
KR (1) KR102514914B1 (es)
CN (1) CN107074804B (es)
AR (1) AR102427A1 (es)
AU (1) AU2015335703B2 (es)
BR (1) BR112017007545A2 (es)
CA (1) CA2965523A1 (es)
CL (1) CL2017001001A1 (es)
CO (1) CO2017004517A2 (es)
CY (1) CY1122549T1 (es)
DK (1) DK3209651T3 (es)
EA (1) EA032361B1 (es)
ES (1) ES2761903T3 (es)
HR (1) HRP20192197T2 (es)
HU (1) HUE048321T2 (es)
IL (1) IL251798B (es)
LT (1) LT3209651T (es)
MA (1) MA40302B1 (es)
ME (1) ME03754B (es)
MX (1) MX374724B (es)
MY (1) MY190568A (es)
PE (1) PE20171239A1 (es)
PH (1) PH12017500724B1 (es)
PL (1) PL3209651T3 (es)
PT (1) PT3209651T (es)
RS (1) RS59707B1 (es)
SG (2) SG11201703187PA (es)
SI (1) SI3209651T1 (es)
SM (1) SMT202000035T1 (es)
TN (1) TN2017000158A1 (es)
TW (1) TWI676618B (es)
WO (1) WO2016065236A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201903621SA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
UA121871C2 (uk) 2014-10-24 2020-08-10 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
US10399988B2 (en) * 2016-07-07 2019-09-03 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
EP3694528A4 (en) 2017-10-13 2021-07-28 The Regents of the University of California MTORC1 MODULATORS
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
JP7545467B2 (ja) 2019-10-04 2024-09-04 ブリストル－マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
US20220009920A1 (en) * 2020-04-10 2022-01-13 Gb005, Inc. Kinase inhibitors
US20230219923A1 (en) * 2020-06-02 2023-07-13 Gb005, Inc. Kinase inhibitors
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
TW202408487A (zh) * 2022-07-06 2024-03-01 美商維維迪昂醫療公司 包含ｗｒｎ解旋酶抑制劑之醫藥組成物
US20240226114A1 (en) * 2022-09-29 2024-07-11 Vividion Therapeutics, Inc. Inhibitors and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0517211B8 (pt) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa composto, composição farmacêutica e seu uso.
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US8518964B2 (en) * 2005-11-22 2013-08-27 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
RU2009113585A (ru) 2006-09-11 2010-10-20 Матрикс Лэборетериз Лтд. (In) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009075830A1 (en) 2007-12-13 2009-06-18 Merck & Co., Inc. Inhibitors of janus kinases
SI2247558T2 (sl) 2008-02-14 2024-10-30 Eli Lilly And Company Nova kontrastna sredstva za zaznavanje nevroloških disfunkcij
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
WO2009153720A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (en) 2009-02-13 2010-08-19 Nextivity, Inc. Remote control for booster
EP2582668B1 (en) * 2010-06-16 2016-01-13 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CN103429595B (zh) 2010-11-15 2015-10-21 Viiv保健英国有限公司 Hiv复制的抑制剂
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
CA2863259A1 (en) 2012-01-10 2013-07-18 Nimbus Iris, Inc. Irak inhibitors and uses thereof
KR20150060839A (ko) 2012-10-26 2015-06-03 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
AR096721A1 (es) * 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
KR102345381B1 (ko) * 2013-06-25 2021-12-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
EA034931B1 (ru) 2014-10-24 2020-04-08 Бристол-Майерс Сквибб Компани Индолкарбоксамидные соединения
SG10201903621SA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds

Also Published As

Publication number Publication date
BR112017007545A2 (pt) 2017-12-19
EA032361B1 (ru) 2019-05-31
WO2016065236A1 (en) 2016-04-28
AU2015335703B2 (en) 2020-05-21
CN107074804A (zh) 2017-08-18
AR102427A1 (es) 2017-03-01
EP3209651A1 (en) 2017-08-30
TW201629014A (zh) 2016-08-16
AU2015335703A1 (en) 2017-06-08
US20170362176A1 (en) 2017-12-21
CN107074804B (zh) 2020-02-18
MY190568A (en) 2022-04-27
KR102514914B1 (ko) 2023-03-27
TWI676618B (zh) 2019-11-11
IL251798A0 (en) 2017-06-29
US10676434B2 (en) 2020-06-09
ME03754B (me) 2021-04-20
HRP20192197T2 (hr) 2020-11-13
MA40302B1 (fr) 2018-10-31
KR20170075756A (ko) 2017-07-03
MA40302A1 (fr) 2018-05-31
SG11201703187PA (en) 2017-05-30
TN2017000158A1 (en) 2018-10-19
PE20171239A1 (es) 2017-08-24
PT3209651T (pt) 2019-12-30
HUE048321T2 (hu) 2020-07-28
JP2017535536A (ja) 2017-11-30
SI3209651T1 (sl) 2019-12-31
PH12017500724A1 (en) 2017-10-09
JP6599983B2 (ja) 2019-10-30
PL3209651T3 (pl) 2020-03-31
SMT202000035T1 (it) 2020-03-13
EP3209651B9 (en) 2020-05-20
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
CA2965523A1 (en) 2016-04-28
ES2761903T3 (es) 2020-05-21
HRP20192197T1 (hr) 2020-03-06
US10266491B2 (en) 2019-04-23
LT3209651T (lt) 2020-01-10
EP3209651B1 (en) 2019-10-23
US20190225583A1 (en) 2019-07-25
CO2017004517A2 (es) 2017-08-31
HRP20192197T8 (hr) 2020-04-03
DK3209651T3 (da) 2020-02-03
EA201790745A1 (ru) 2017-08-31
RS59707B1 (sr) 2020-01-31
CL2017001001A1 (es) 2017-11-24
SG10201903619YA (en) 2019-05-30
IL251798B (en) 2020-08-31
CY1122549T1 (el) 2021-01-27
US20200255377A1 (en) 2020-08-13
PH12017500724B1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
MX374724B (es) Derivados de carbazol.
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CO2020000145A2 (es) Carboxamidas como moduladores de los canales de sodio
MX2023000812A (es) Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2019001674A1 (es) Inhibidores de imidazopirazina de tirosina quinasa de bruton.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
CO2017002998A2 (es) Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1
UY35369A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX2017016344A (es) Compuestos de benzoxacepina oxazolidinona y metodos de uso.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CR20160537A (es) Inhibidor de fosfoinosítido 3-quinasa delta para su uso medico
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
PE20211548A1 (es) Compuesto de triazina y su uso para fines medicos
UY35625A (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
MX2018004664A (es) Antagonistas de ep4.
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
SV2017005354A (es) Derivados de quinolizinona como inhibidores de pi3k
CL2018000391A1 (es) Combinaciones farmacéuticas y su uso

Legal Events

Date Code Title Description
FG Grant or registration